RELX NV (RENX)

21.19
0.58 2.66
NYSE : Commercial Services
Prev Close 21.77
Open 21.49
Day Low/High 21.18 / 21.55
52 Wk Low/High 20.06 / 23.30
Volume 547.93K
Avg Volume 84.90K
Exchange NYSE
Shares Outstanding 1.05B
Market Cap 21.72B
EPS 1.10
P/E Ratio 9.06
Div & Yield 0.45 (2.08%)

Latest News

RenalytixAI And University Medical Center Groningen To Evaluate KidneyIntelX™ For Early Identification And Guiding Therapeutic Treatment Of Diabetic Kidney Disease

RenalytixAI And University Medical Center Groningen To Evaluate KidneyIntelX™ For Early Identification And Guiding Therapeutic Treatment Of Diabetic Kidney Disease

NEW YORK, May 7, 2019 /PRNewswire/ -- Renalytix AI plc (LON: RENX), a developer of artificial intelligence-enabled clinical diagnostics for kidney disease, announced today a collaboration with University Medical Center Groningen (UMCG), Netherlands, to...

FDA Grants Breakthrough Device Designation To KidneyIntelX™

FDA Grants Breakthrough Device Designation To KidneyIntelX™

Provides Priority Regulatory Review of AI-Enabled Diagnostic for Fast-Progressing Kidney Disease

RenalytixAI Forms Core Investigator Group For Kidney Transplant Advanced Diagnostic Program

RenalytixAI Forms Core Investigator Group For Kidney Transplant Advanced Diagnostic Program

Investigators include leading transplant clinicians from Emory University, the University of Manitoba, the Westmead Hospital Sydney, and Icahn School of Medicine at Mount Sinai

RenalytixAI And AKESOgen In Joint Venture Partnership For Expanded Testing Capacity And Pharma Services

RenalytixAI And AKESOgen In Joint Venture Partnership For Expanded Testing Capacity And Pharma Services

NEW YORK, Feb. 13, 2019 /PRNewswire/ --  RenalytixAI (AIM: RENX), a developer of artificial intelligence-enabled diagnostics for kidney disease, today announced the completion of a joint venture partnership agreement with AKESOgen, an industry-leading...

RenalytixAI Expands Leadership Team To Support Launch Of AI-Enabled Diagnostics For Kidney Disease

RenalytixAI Expands Leadership Team To Support Launch Of AI-Enabled Diagnostics For Kidney Disease

Company Adds Clinical and Data Security Expertise to Support KidneyIntelX Clinical Validation, Software and Regulatory Programs

RenalytixAI Initiates Clinical Validation Study Of AI-Enabled KidneyIntelX™ For Diagnosing Fast-Progressing Kidney Disease

RenalytixAI Initiates Clinical Validation Study Of AI-Enabled KidneyIntelX™ For Diagnosing Fast-Progressing Kidney Disease

Validation study to assess approximately 5,000 patients with participation from a multi-center group of leading U.S. investigators

RELX Enters Oversold Territory

RELX Enters Oversold Territory

The DividendRank formula at Dividend Channel ranks a coverage universe of thousands of dividend stocks, according to a proprietary formula designed to identify those stocks that combine two important characteristics — strong fundamentals and a valuation that looks inexpensive. RELX NV presently has an above average rank, in the top 50% of the coverage universe, which suggests it is among the top most "interesting" ideas that merit further research by investors.